(Q46638059)

23 December 2017

title

Lipoxygenase pathway receptor expression in ovarian cancer (English)

1 reference

23 December 2017

1 reference

Rodney P Rocconi

1

1 reference

23 December 2017

Tyler O Kirby

2

1 reference

23 December 2017

Robert S Seitz

3

1 reference

23 December 2017

Rod Beck

4

1 reference

23 December 2017

J Michael Straughn

5

1 reference

23 December 2017

Ronald D Alvarez

6

1 reference

23 December 2017

Warner K Huh

7

1 reference

23 December 2017

publication date

1 April 2008

1 reference

23 December 2017

published in

Reproductive Sciences

1 reference

23 December 2017

volume

15

1 reference

23 December 2017

issue

3

1 reference

23 December 2017

page(s)

321-326

1 reference

23 December 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

A novel anti-pancreatic cancer agent, LY293111.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Cyclooxygenase and lipoxygenase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Effect of LY293111 in combination with gemcitabine in colonic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108316390

21 January 2018

Identifiers

DOI

10.1177/1933719108316390

1 reference

23 December 2017

PubMed ID

18421027

1 reference

23 December 2017